Scientists are “re-imagining ultrasound technology to develop a treatment that can liquefy cancer cells in the body using microscopic bubbles”.
News
ViiV submits regulatory application to EMA for investigational HIV combo
The application is for cabotegravir and Edurant (rilpivirine) as the first monthly, injectable treatment for HIV.
Skin cancer rates rocket 45% in 10 years
Rates have increased by more than a third (35%) for women and by almost three-fifths (55%) for men.
NHS Confederation responds to PM’s promise to ‘fix crisis’
But the organisation says it will “need more details of exactly how this will be achieved”.
FDA accepts Brinavess resubmission
The FDA initially cited insufficient data and refused to accept the initial submission in August 2017.
New inquiry into healthy ageing launched
Increasing health span has been adopted as a policy objective by the UK Government in the Industrial Strategy’s “Ageing Society”.
Lynparza now available on Cancer Drugs Fund
The treatment reduces the risk of disease progression or death in such patients by 70% vs placebo.
CHMP recommends five new medicines
Stelara, Keytruda and Tecentriq were also among the extensions of therapeutic indication.
£20m investment to help young people find NHS careers
The funding will support 10,000 young people from all backgrounds to get a career in the NHS.
GSK Q2 figures boosted by vaccine sales
The company has readjusted its prediction for its earnings per share to decline in the range of -3% to -5% at CER, as opposed to the previous -5% to -9%.
NICE to form alliance to produce chronic asthma guideline
The guideline aims to support health professionals in making accurate diagnoses and providing effective treatments.
Advanz, Morningside, Alliance accused of illegal market sharing
The CMA alleges that Alliance Healthcare bought equal volumes of nitrofurantoin from the companies to discourage competing.
AZ’ roxadustat successful in late-stage trial
The trial met its primary efficacy endpoint of a mean change in haemoglobin from baseline averaged over weeks 23-27.
Gilead licenses respiratory, herpes antiviral research programs from Novartis
The antivirus programs include investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.
NICE reveals ‘health technology evaluation methods’ review
The review will cover NICE’s technology appraisals, highly specialised technologies, medical technologies, and diagnostics assessment programmes.
